Astellas Pharma, Inc. has two new growth drivers – the women’s health drug Veozah (fezolinetant) and the eye disease drug Izervay (avacincaptad pegol) – that are expected to help make up for the loss of revenue from Myrbetriq (mirabegron) to generics this year and eventually sales declines for the company’s biggest seller, Xtandi (enzalutamide).
Astellas’s US Commercial Head Petroutsas On New Launches
The Japanese pharma’s new US commercial head Michael Petroutsas talked to Scrip about the launches of Veozah and Izervay.
More from New Products
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.